Hope for young leukemia patients: new 3-Drug combo trial launches
NCT ID NCT05317403
Summary
This study is testing whether adding a drug called venetoclax to two other medications (5-azacitidine and vorinostat) followed by standard chemotherapy can better control a severe blood cancer called acute myeloid leukemia (AML) in children and young adults. It is for patients whose cancer has returned after treatment or did not respond to previous therapies. The main goal of this early-phase trial is to find a safe dose and see if this combination leads to deeper, longer-lasting responses.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.